ABUS
Arbutus Biopharma Corp
+0.02 (+0.40%)5.07USD1.2M成交股數–市值–本益比(近四季)–股價營收比-90.6%營收年增(近四季)2026-11-16下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0 · 0 |
| 近 180 天 淨額 | 0 |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-02 | 02-02 | Androski Lindsay | President and CEO | A 獲配股票 | 28.0K | – | – | 28.0K | SEC |
| 2026-02-02 | 02-02 | Nguyen Tuan | Chief Financial Officer | A 獲配股票 | 73.5K | – | – | 73.5K | SEC |
| 2025-02-14 | 02-19 | HASTINGS DAVID C | Chief Financial Officer | A 獲配股票 | 90.1K | – | – | 250K | SEC |
| 2025-02-14 | 02-19 | McElhaugh Michael J. | Interim President & CEO | A 獲配股票 | 177K | – | – | 1.7M | SEC |
| 2025-02-14 | 02-19 | Naftzger J. Christopher | General Counsel and CCO | A 獲配股票 | 54.3K | – | – | 141K | SEC |
| 2025-02-14 | 02-19 | Sims Karen | Chief Medical Officer | A 獲配股票 | 49.3K | – | – | 155K | SEC |
| 2025-02-04 | 02-05 | Naftzger J. Christopher | General Counsel and CCO | S 公開市場賣出(10b5-1) | 11.3K | 3.28 | 37K | 86.2K | SEC |
| 2025-02-04 | 02-05 | McElhaugh Michael J. | Interim President & CEO | S 公開市場賣出(10b5-1) | 23.8K | 3.28 | 78K | 1.5M | SEC |
| 2025-02-04 | 02-05 | Sims Karen | Chief Medical Officer | S 公開市場賣出(10b5-1) | 19.3K | 3.28 | 63K | 106K | SEC |
| 2025-02-04 | 02-05 | HASTINGS DAVID C | Chief Financial Officer | S 公開市場賣出(10b5-1) | 22.2K | 3.28 | 73K | 160K | SEC |
| 2024-08-14 | 08-16 | MANCHESTER KEITH S | Director | M 選擇權執行 | 54.9K | 0.56 | 31K | 54.9K | SEC |
| 2024-08-14 | 08-16 | MANCHESTER KEITH S | Director | S 公開市場賣出 | 8.8K | 3.69 | 33K | 46.1K | SEC |
| 2024-02-02 | 02-05 | HASTINGS DAVID C | Chief Financial Officer | S 公開市場賣出(10b5-1) | 9.6K | 2.31 | 22K | 182K | SEC |
| 2024-02-02 | 02-05 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 10.0K | 2.31 | 23K | 1.5M | SEC |
| 2024-02-02 | 02-05 | Sims Karen | Chief Medical Officer | S 公開市場賣出(10b5-1) | 4.4K | 2.31 | 10K | 126K | SEC |
| 2024-02-02 | 02-05 | McElhaugh Michael J. | Interim President & CEO | S 公開市場賣出(10b5-1) | 10.2K | 2.31 | 23K | 1.5M | SEC |
| 2024-02-01 | 02-05 | McElhaugh Michael J. | Interim President & CEO | A 獲配股票 | 124K | – | – | 1.5M | SEC |
| 2024-02-01 | 02-05 | Naftzger J. Christopher | General Counsel and CCO | A 獲配股票 | 95.1K | – | – | 95.1K | SEC |
| 2024-02-01 | 02-05 | Sofia Michael J. | Chief Scientific Officer | A 獲配股票 | 110K | – | – | 1.5M | SEC |
| 2024-02-01 | 02-05 | HASTINGS DAVID C | Chief Financial Officer | A 獲配股票 | 113K | – | – | 192K | SEC |
| 2024-02-01 | 02-05 | Sims Karen | Chief Medical Officer | A 獲配股票 | 101K | – | – | 130K | SEC |
| 2023-02-01 | 02-03 | Sofia Michael J. | Chief Scientific Officer | A 獲配股票 | 82.2K | – | – | 1.4M | SEC |
| 2023-02-01 | 02-03 | Howard Elizabeth | EVP, GC, Compliance | A 獲配股票 | 69.7K | – | – | 86.0K | SEC |
| 2023-02-01 | 02-03 | Collier William H. | President and CEO | A 獲配股票 | 217K | – | – | 217K | SEC |
| 2023-02-01 | 02-03 | HASTINGS DAVID C | Chief Financial Officer | A 獲配股票 | 79.0K | – | – | 79.0K | SEC |
| 2023-02-01 | 02-03 | McElhaugh Michael J. | Chief Business Officer | A 獲配股票 | 83.7K | – | – | 1.4M | SEC |
| 2021-12-01 | 12-03 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 200K | 5.09 | 1.0M | 1.3M | SEC |
| 2021-10-18 | 10-20 | Roivant Sciences Ltd. | TenPercentOwner | C 轉換 | 22.8M | – | – | 38.8M | SEC |
| 2021-02-09 | 02-10 | McElhaugh Michael J. | Chief Business Officer | S 公開市場賣出 | 20.0K | 5.00 | 100K | 1.3M | SEC |
| 2020-12-14 | 12-16 | McElhaugh Michael J. | Chief Business Officer | S 公開市場賣出 | 30.0K | 5.00 | 150K | 1.3M | SEC |
| 2020-12-14 | 12-16 | McElhaugh Michael J. | Chief Business Officer | S 公開市場賣出 | 10.0K | 5.00 | 50K | 1.3M | SEC |
| 2020-07-23 | 07-27 | McElhaugh Michael J. | Chief Business Officer | S 公開市場賣出 | 20.0K | 5.01 | 100K | 1.4M | SEC |
| 2018-11-28 | 11-30 | Murray Mark J. | Director | M 選擇權執行 | 25.0K | 1.35 | 34K | 341K | SEC |
| 2018-08-13 | 08-15 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 4.3K | 9.51 | 40K | 167K | SEC |
| 2018-08-13 | 08-14 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 4.3K | 9.51 | 40K | 1.5M | SEC |
| 2018-07-11 | 07-13 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 10.0K | 10.00 | 100K | 1.5M | SEC |
| 2018-07-09 | 07-10 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 10.0K | 8.91 | 89K | 1.5M | SEC |
| 2018-07-06 | 07-10 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 10.0K | 8.45 | 85K | 1.5M | SEC |
| 2018-07-05 | 07-06 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 10.0K | 8.40 | 84K | 1.5M | SEC |
| 2018-07-03 | 07-06 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 10.0K | 8.00 | 80K | 1.5M | SEC |
| 2018-04-17 | 04-17 | Murray Mark J. | President & CEO | M 選擇權執行 | 27.0K | 0.35 | 9K | 316K | SEC |
| 2017-10-03 | 10-05 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 10.0K | 8.00 | 80K | 1.6M | SEC |
| 2017-08-15 | 08-17 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 20.0K | 3.68 | 74K | 171K | SEC |
| 2017-08-15 | 08-17 | Sofia Michael J. | Chief Scientific Officer | S 公開市場賣出 | 10.0K | 3.75 | 38K | 191K | SEC |
| 2016-08-16 | 08-18 | Abrams Michael J. | Managing Director | M 選擇權執行 | 14.2K | 0.35 | 5K | 42.1K | SEC |
| 2016-06-16 | 06-20 | Murray Mark J. | President & CEO | X 選擇權履約 | 5.0K | 2.57 | 13K | 289K | SEC |
| 2015-09-11 | 09-15 | Abrams Michael J. | Managing Director | M 選擇權執行 | 17.0K | 0.44 | 7K | 27.9K | SEC |
| 2015-09-11 | 09-15 | Murray Mark J. | President & CEO | M 選擇權執行 | 219K | 0.44 | 97K | 284K | SEC |
| 2015-08-24 | 08-26 | HENRIQUES RICHARD C JR | Director | P 公開市場買進 | 1.0K | 6.95 | 7K | 1.0K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| Two Seas Capital LP | 19.1M | 91.7M | +538K (+3%) | 加碼 |
| MORGAN STANLEY | 17.7M | 85.0M | −8.2M (-32%) | 減碼 |
| Whitefort Capital Management, LP | 15.8M | 75.8M | +863K (+6%) | 加碼 |
| BlackRock, Inc. | 13.8M | 66.1M | +799K (+6%) | 加碼 |
| STATE STREET CORP | 7.9M | 37.8M | +1.5M (+24%) | 加碼 |
| Rubric Capital Management LP | 7.5M | 36.2M | +907K (+14%) | 加碼 |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.0M | 33.7M | +322K (+5%) | 加碼 |
| BARCLAYS PLC | 4.2M | 20.2M | −108K (-3%) | 減碼 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.1M | 19.8M | +346K (+9%) | 加碼 |
| GOLDMAN SACHS GROUP INC | 3.5M | 16.8M | +2.4M (+219%) | 加碼 |
| BANK OF AMERICA CORP /DE/ | 2.6M | 12.7M | +963K (+57%) | 加碼 |
| BlackBarn Capital Partners LP | 2.5M | 12.0M | 不變 | 持平 |
| Legal & General Group Plc | 2.5M | 11.8M | +64.7K (+3%) | 加碼 |
| Woodline Partners LP | 2.3M | 11.0M | +272K (+14%) | 加碼 |
| Jefferies Financial Group Inc. | 1.7M | 8.2M | −182K (-10%) | 減碼 |
| NOMURA HOLDINGS INC | 1.6M | 7.9M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.5M | 7.4M | +149K (+11%) | 加碼 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.4M | 6.9M | +30.1K (+2%) | 加碼 |
| NORTHERN TRUST CORP | 1.4M | 6.8M | +141K (+11%) | 加碼 |
| OSAIC HOLDINGS, INC. | 1.3M | 6.5M | −261 (-0%) | 減碼 |
| ADAR1 Capital Management, LLC | 1.3M | 6.1M | −1.9M (-60%) | 減碼 |
| Deltroit Asset Management (UK) LLP | 1.2M | 5.8M | +400K (+50%) | 加碼 |
| VANGUARD FIDUCIARY TRUST CO | 1.1M | 5.4M | +72.3K (+7%) | 加碼 |
| CITIGROUP INC | 879K | 4.2M | −19.2K (-2%) | 減碼 |
| BANK OF MONTREAL /CAN/ | 778K | 3.7M | −4.8K (-1%) | 減碼 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 177 +9 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 34 / 25 / 63 / 38 |
| 機構合計持股 · 佔流通股 | 141M |
| 合計季末市值 | 673M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 18.9M |
|---|---|
| 與上期比 | +2.5% |
| 佔流通股數 | –(外國發行人不算) |
| 日均成交量 | 6.1M |
| 回補天數 | 3.1 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 18.9M | +2.5% | – | 6.1M | 3.1 |
| 2026-08-14 | 18.5M | -8.8% | – | 1.2M | 15.1 |
| 2026-07-31 | 20.2M | +3.0% | – | 1.5M | 13.7 |
| 2026-07-15 | 19.7M | +14.8% | – | 2.7M | 7.4 |
| 2026-06-30 | 17.1M | -2.4% | – | 3.5M | 4.9 |
| 2026-06-15 | 17.5M | +3.2% | – | 1.3M | 14.0 |
| 2026-05-29 | 17.0M | +3.3% | – | 1.8M | 9.2 |
| 2026-05-15 | 16.4M | -7.4% | – | 962K | 17.1 |
| 2026-04-30 | 17.7M | -0.3% | – | 2.5M | 7.2 |
| 2026-04-15 | 17.8M | +10.1% | – | 1.6M | 11.4 |
| 2026-03-31 | 16.2M | -1.4% | – | 2.3M | 7.0 |
| 2026-03-13 | 16.4M | +11.2% | – | 3.9M | 4.2 |
| 2026-02-27 | 14.8M | -1.6% | – | 1.6M | 9.5 |
| 2026-02-13 | 15.0M | +10.6% | – | 2.3M | 6.4 |
| 2026-01-30 | 13.6M | +3.8% | – | 1.8M | 7.5 |
| 2026-01-15 | 13.1M | +4.2% | – | 1.1M | 12.2 |
| 2025-12-31 | 12.5M | +16.7% | – | 1.5M | 8.6 |
| 2025-12-15 | 10.7M | -4.2% | – | 1.2M | 9.3 |
| 2025-11-28 | 11.2M | +6.1% | – | 1.1M | 9.9 |
| 2025-11-14 | 10.6M | +6.5% | – | 984K | 10.7 |
| 2025-10-31 | 9.9M | +0.5% | – | 958K | 10.4 |
| 2025-10-15 | 9.9M | -2.7% | – | 937K | 10.5 |
| 2025-09-30 | 10.1M | -9.2% | – | 1.1M | 9.6 |
| 2025-09-15 | 11.2M | +5.8% | – | 2.2M | 5.2 |
| 2025-08-29 | 10.5M | -15.7% | – | 948K | 11.1 |
| 2025-08-15 | 12.5M | -3.6% | – | 687K | 18.2 |